LAUSR

Extracorporeal membrane oxygenation (ECMO) is increasingly used as an emergent or salvage modality in patients with cardiovascular or pulmonary collapse. Percutaneous cannulation can be quickly performed with ultrasound, transesophageal echocardiogram (TEE) or fluoroscopic guidance. However, the emergent nature of ECMO does not allow time for the placement of a preclosure device in the artery. Surgical decannulation of ECMO can be associated with bleeding and wound complications. The MANTA vascular closure device (VCD) (Essential Medical Inc, Malvern, Pennsylvania) is a collagen‐based technology that is food and drug administration (FDA) approved, allowing closure of femoral arterial access sites in endovascular catheterization procedures with bore sizes ranging from 12F to 25F (outer diameter) using an 18F access catheter (Figure 1). The closure unit includes a resorbable intravascular toggle, an extravascular hemostatic bovine collagen pad, a connecting polyester suture, and a stainless‐steel suture lock (Figure 2). Manta VCD is a postclosure technique, not requiring any added steps during initial ECMO cannulation. We describe the first use of the MANTA VCD in the decannulation of an ECMO patient in the United States.